Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Alles über Alzheimer : Antworten auf die wichtigsten Fragen
| Alles über Alzheimer : Antworten auf die wichtigsten Fragen |
| Autore | Stoppe Gabriela |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Kreuz Verlag, 2011 |
| Descrizione fisica | 1 online resource (234 p.) |
| Disciplina | 618.976831 |
| Soggetto topico |
Alzheimer''s disease
Children and older people Dementia |
| ISBN |
9783783181685
3783181682 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | ger |
| Nota di contenuto |
Intro -- Vorwort -- Was bedeutet Demenz für uns? -- Jung und gesund, alt und Alzheimer? -- Alzheimer - immer noch stigmatisiert -- Was ist eine Alzheimer-Demenz? -- Was ist eine Demenz? -- Alois Alzheimers Entdeckung -- Die Stadien der Erkrankung -- Eiweißablagerungen und Durchblutung -- Risikofaktoren -- Das Erscheinungsbild und der Verlauf von Demenzerkrankungen -- Die Alzheimer-Demenz -- Die vaskuläre Demenz -- Demenzen bei Parkinson-Krankheit und Lewy-Körper-Demenzen -- Frontotemporale Degenerationen -- Andere Demenzen -- Wie erkennt man eine Demenz und welche Untersuchungen sollten durchgeführt werden? -- Suchverfahren geben erste Hinweise -- Vorgeschichte, Risikofaktoren und alle anderen individuellen Gegebenheiten werden einbezogen -- Wer macht eine Demenzabklärung? -- Die Abgrenzung zum noch normalen Alter -- Die Abgrenzung zur Depression -- Die leichte kognitive Beeinträchtigung -- Wie kann der Alzheimer-Demenz vorgebeugt und wie kann sie behandelt werden -- Empfehlungen zur Vorbeugung -- Die Behandlung: ein umfassendes Management -- Medikamentöse Behandlung -- Die Wirkung der Antidementiva -- Die Frage der Wirksamkeit -- Zulassungskriterien für Medikamente -- Behandlung mit anderen Psychopharmaka -- Die Behandlung anderer Demenzen -- Nichtmedikamentöse Maßnahmen -- Trainingsverfahren -- Stimulierende Verfahren -- Die Gestaltung des Umfelds und Umgangs -- Besonderheiten in der Versorgung: Memory Clinic, Krankenhaus, Pflegeheim, private Wohnsituation -- Das Angebot von Gedächtnissprechstunden oder Memory Clinics -- Die Behandlung im Krankenhaus -- Die Behandlung im Pflegeheim -- Die Gestaltung der privaten Wohnsituation -- Weitere Hilfen für Betroffene und Angehörige -- Eine allein nicht zu bewältigende Aufgabe -- Gewalt und Missbrauch -- Hilfe lernen -- Freiwillige Hilfsangebote -- Wann soll man Hilfe suchen?.
Ethische und rechtliche Aspekte -- Aufklärung -- Geschäfts- und Urteilsfähigkeit -- Patientenverfügung -- Testierfähigkeit -- Fahrtauglichkeit -- PEG-Sonden -- Sterbehilfe und Sterben bei Demenz -- Probleme der Forschung -- Ein Ausblick in die Zukunft -- Die Einstellung zur Krankheit und zum Altern muss sich ändern -- Gegen die Problemverleugnung -- Wird es therapeutischen Fortschritt geben? -- Für eine demenzgerechte Umwelt -- Gegen Panikrechnungen -- Anmerkungen -- Literatur -- Hilfreiche Links/Kontakte -- Register der Fragen - Wegweiser zu den Antworten. |
| Altri titoli varianti | Alles über Alzheimer |
| Record Nr. | UNINA-9910155796503321 |
Stoppe Gabriela
|
||
| Kreuz Verlag, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
BACE [[electronic resource] ] : lead target for orchestrated therapy of Alzheimer's disease / / edited by Varghese John
| BACE [[electronic resource] ] : lead target for orchestrated therapy of Alzheimer's disease / / edited by Varghese John |
| Pubbl/distr/stampa | Hoboken, NJ, : John Wiley & Sons, c2010 |
| Descrizione fisica | 1 online resource (284 p.) |
| Disciplina | 618.976831 |
| Altri autori (Persone) | JohnVarghese <1958-> |
| Soggetto topico |
Alzheimer's disease - Chemotherapy
Aspartic proteinases - Inhibitors - Therapeutic use Amyloid beta-protein precursor |
| ISBN |
1-282-49175-X
9786612491757 0-470-59408-X 0-470-59407-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BACE; CONTENTS; PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; CHAPTER 1 BACE, APP PROCESSING, AND SIGNAL TRANSDUCTION IN ALZHEIMER'S DISEASE; 1.1 Introduction; 1.2 BACE Cleavage of APP as a Molecular Switching Mechanism; 1.3 AD: An Imbalance in Cellular Dependence?; 1.4 BACE Cleavage, Caspase Cleavage, and Neuronal Trophic Dependence; 1.5 BACE Cleavage of APP, Dependence Receptors, and Alzheimer Pathology; 1.6 Key Mutations Proximal of APP Processing to Aβ; 1.7 Final Remarks; CHAPTER 2 IDENTIFICATION OF BACE AS A TARGET IN ALZHEIMER'S DISEASE; 2.1 Introduction; 2.2 The Search for β-Secretase
2.3 Validation of the BACE Target 2.4 Final Remarks; CHAPTER 3 BACE BIOLOGICAL ASSAYS; 3.1 Introduction; 3.2 Clinical and Physiological Hallmarks of Alzheimer's Disease (AD); 3.3 APP Processing; 3.4 Aspartyl Protease Classification; 3.5 BACE Structure; 3.6 Mechanism, Kinetics, Inhibition, and Specificity; 3.7 Assay Strategies for Inhibitor Finding and Development; 3.8 Common Assays Used to Identify and Study Inhibitors; 3.9 BACE Assays; 3.10 Final Remarks; CHAPTER 4 PEPTIDIC, PEPTIDOMIMETIC, AND HTS-DERIVED BACE INHIBITORS; 4.1 Introduction; 4.2 Elan/Pharmacia (Pfizer) 4.3 Oklahoma Medical Research Foundation (OMRF)/Multiple Collaborators 4.4 Eli Lilly; 4.5 Merck; 4.6 GlaxoSmithKline; 4.7 Schering Plough; 4.8 Bristol-Myers Squibb; 4.9 Novartis; 4.10 Amgen; 4.11 Wyeth; 4.12 Final Remarks; CHAPTER 5 FRAGMENT-BASED APPROACHES FOR IDENTIFICATION OF BACE INHIBITORS; 5.1 Introduction; 5.2 Biophysical Methods Applied to BACE Fragment Screens; 5.3 BACE Inhibitors Identified by Fragment Screening; 5.4 Final Remarks; CHAPTER 6 STRUCTURE-BASED DESIGN OF BACE INHIBITORS: TECHNICAL AND PRACTICAL ASPECTS OF PREPARATION, 3-DIMENSIONAL STRUCTURE, AND COMPUTATIONAL ANALYSIS 6.1 Introduction 6.2 Preparation of BACE for Structural Studies; 6.3 Crystallographic Studies of BACE; 6.4 Structural Studies with BACE Inhibitors: Peptidomimetics and Nonpeptidomimetics; 6.5 Computational Approaches; 6.6 Final Remarks; CHAPTER 7 PHARMACOLOGICAL MODELS FOR PRECLINICAL TESTING: FROM MOUSE TO DOG TO NONHUMAN PRIMATES; 7.1 Introduction; 7.2 BACE 1 and Mouse Models of AD; 7.3 Testing BACE Inhibitors in the Canine Model of Human Aging and AD; 7.4 BACE Inhibitors and Nonhuman Primates; 7.5 Final Remarks CHAPTER 8 ADSORPTION, DISTRIBUTION, METABOLISM, EXCRETION (ADME), EFFICACY, AND TOXICOLOGY FOR BACE INHIBITORS 8.1 Introduction; 8.2 Development of BACE Inhibitors with Optimized ADME Properties; 8.3 In Vivo Efficacy of BACE Inhibitors; 8.4 Toxicology of BACE Inhibitors; 8.5 Final Remarks; CHAPTER 9 CLINICAL TRIALS FOR DISEASE-MODIFYING DRUGS SUCH AS BACE INHIBITORS; 9.1 Introduction; 9.2 Update on Beta-Amyloid Therapies in Clinical Development; 9.3 Clinical Development of BACE Inhibitors and Other Disease-Modifying Drugs; 9.4 Final Remarks CHAPTER 10 FUTURE STRATEGIES FOR DEVELOPMENT OF NOVEL BACE INHIBITORS: ANTI-APP β-SITE ANTIBODY AND APP BINDING SMALL MOLECULE APPROACHES FOR ALZHEIMER'S DISEASE |
| Record Nr. | UNINA-9910140616703321 |
| Hoboken, NJ, : John Wiley & Sons, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
BACE : lead target for orchestrated therapy of Alzheimer's disease / / edited by Varghese John
| BACE : lead target for orchestrated therapy of Alzheimer's disease / / edited by Varghese John |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, NJ, : John Wiley & Sons, c2010 |
| Descrizione fisica | 1 online resource (284 p.) |
| Disciplina | 618.976831 |
| Altri autori (Persone) | JohnVarghese <1958-> |
| Soggetto topico |
Alzheimer's disease - Chemotherapy
Aspartic proteinases - Inhibitors - Therapeutic use Amyloid beta-protein precursor |
| ISBN |
9786612491757
9781282491755 128249175X 9780470594087 047059408X 9780470594070 0470594071 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BACE; CONTENTS; PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; CHAPTER 1 BACE, APP PROCESSING, AND SIGNAL TRANSDUCTION IN ALZHEIMER'S DISEASE; 1.1 Introduction; 1.2 BACE Cleavage of APP as a Molecular Switching Mechanism; 1.3 AD: An Imbalance in Cellular Dependence?; 1.4 BACE Cleavage, Caspase Cleavage, and Neuronal Trophic Dependence; 1.5 BACE Cleavage of APP, Dependence Receptors, and Alzheimer Pathology; 1.6 Key Mutations Proximal of APP Processing to Aβ; 1.7 Final Remarks; CHAPTER 2 IDENTIFICATION OF BACE AS A TARGET IN ALZHEIMER'S DISEASE; 2.1 Introduction; 2.2 The Search for β-Secretase
2.3 Validation of the BACE Target 2.4 Final Remarks; CHAPTER 3 BACE BIOLOGICAL ASSAYS; 3.1 Introduction; 3.2 Clinical and Physiological Hallmarks of Alzheimer's Disease (AD); 3.3 APP Processing; 3.4 Aspartyl Protease Classification; 3.5 BACE Structure; 3.6 Mechanism, Kinetics, Inhibition, and Specificity; 3.7 Assay Strategies for Inhibitor Finding and Development; 3.8 Common Assays Used to Identify and Study Inhibitors; 3.9 BACE Assays; 3.10 Final Remarks; CHAPTER 4 PEPTIDIC, PEPTIDOMIMETIC, AND HTS-DERIVED BACE INHIBITORS; 4.1 Introduction; 4.2 Elan/Pharmacia (Pfizer) 4.3 Oklahoma Medical Research Foundation (OMRF)/Multiple Collaborators 4.4 Eli Lilly; 4.5 Merck; 4.6 GlaxoSmithKline; 4.7 Schering Plough; 4.8 Bristol-Myers Squibb; 4.9 Novartis; 4.10 Amgen; 4.11 Wyeth; 4.12 Final Remarks; CHAPTER 5 FRAGMENT-BASED APPROACHES FOR IDENTIFICATION OF BACE INHIBITORS; 5.1 Introduction; 5.2 Biophysical Methods Applied to BACE Fragment Screens; 5.3 BACE Inhibitors Identified by Fragment Screening; 5.4 Final Remarks; CHAPTER 6 STRUCTURE-BASED DESIGN OF BACE INHIBITORS: TECHNICAL AND PRACTICAL ASPECTS OF PREPARATION, 3-DIMENSIONAL STRUCTURE, AND COMPUTATIONAL ANALYSIS 6.1 Introduction 6.2 Preparation of BACE for Structural Studies; 6.3 Crystallographic Studies of BACE; 6.4 Structural Studies with BACE Inhibitors: Peptidomimetics and Nonpeptidomimetics; 6.5 Computational Approaches; 6.6 Final Remarks; CHAPTER 7 PHARMACOLOGICAL MODELS FOR PRECLINICAL TESTING: FROM MOUSE TO DOG TO NONHUMAN PRIMATES; 7.1 Introduction; 7.2 BACE 1 and Mouse Models of AD; 7.3 Testing BACE Inhibitors in the Canine Model of Human Aging and AD; 7.4 BACE Inhibitors and Nonhuman Primates; 7.5 Final Remarks CHAPTER 8 ADSORPTION, DISTRIBUTION, METABOLISM, EXCRETION (ADME), EFFICACY, AND TOXICOLOGY FOR BACE INHIBITORS 8.1 Introduction; 8.2 Development of BACE Inhibitors with Optimized ADME Properties; 8.3 In Vivo Efficacy of BACE Inhibitors; 8.4 Toxicology of BACE Inhibitors; 8.5 Final Remarks; CHAPTER 9 CLINICAL TRIALS FOR DISEASE-MODIFYING DRUGS SUCH AS BACE INHIBITORS; 9.1 Introduction; 9.2 Update on Beta-Amyloid Therapies in Clinical Development; 9.3 Clinical Development of BACE Inhibitors and Other Disease-Modifying Drugs; 9.4 Final Remarks CHAPTER 10 FUTURE STRATEGIES FOR DEVELOPMENT OF NOVEL BACE INHIBITORS: ANTI-APP β-SITE ANTIBODY AND APP BINDING SMALL MOLECULE APPROACHES FOR ALZHEIMER'S DISEASE |
| Record Nr. | UNINA-9910810075403321 |
| Hoboken, NJ, : John Wiley & Sons, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of imaging the Alzheimer brain [[electronic resource] /] / edited by J. Wesson Ashford ... [et al.]
| Handbook of imaging the Alzheimer brain [[electronic resource] /] / edited by J. Wesson Ashford ... [et al.] |
| Pubbl/distr/stampa | Amsterdam, The Netherlands, : IOS Press, 2011 |
| Descrizione fisica | 1 online resource (824 p.) |
| Disciplina |
618.97
618.976831 |
| Altri autori (Persone) | AshfordJ. Wesson |
| Collana | Advances in Alzheimer's disease |
| Soggetto topico |
Alzheimer's disease - Imaging
Brain - Imaging |
| Soggetto genere / forma | Electronic books. |
| ISBN |
6613289930
1-283-28993-8 9786613289933 1-60750-793-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. Imaging the Alzheimer's brain : the pathology and pathophysiolgical bases of Alzheimer's disease : implications for advancing diagnostic imaging -- section 2. Structural imaging to diagnose and measure Alzheimer-related brain changes -- section 3. Imaging of cerebral blood, flow, glucose metabolism, amyloid plaques and neurofibrilary tangles in AD -- section 4. Current advances in functional magnetic resonance imaging for detecting Alzheimer's disease -- section 5. Electromagnetic brain mapping : EEG, EP, ERP, and their magnetic equivalents -- section 6. Diffusion tensor imaging -- section 7. Magenetic resonance spectroscopy -- section 8. Longitudinal neuroimaging measures : windows into progression of disease and potential endpoints for clinical trials -- section 9. Vascular changes in the brain causing dementia and contributing to Alzheimer's disease -- section 10. Neuroimaging in the context of Alzheimer's disease. |
| Record Nr. | UNINA-9910457762103321 |
| Amsterdam, The Netherlands, : IOS Press, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of imaging the Alzheimer brain [[electronic resource] /] / edited by J. Wesson Ashford ... [et al.]
| Handbook of imaging the Alzheimer brain [[electronic resource] /] / edited by J. Wesson Ashford ... [et al.] |
| Pubbl/distr/stampa | Amsterdam, The Netherlands, : IOS Press, 2011 |
| Descrizione fisica | 1 online resource (824 p.) |
| Disciplina |
618.97
618.976831 |
| Altri autori (Persone) | AshfordJ. Wesson |
| Collana | Advances in Alzheimer's disease |
| Soggetto topico |
Alzheimer's disease - Imaging
Brain - Imaging |
| ISBN |
6613289930
1-283-28993-8 9786613289933 1-60750-793-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. Imaging the Alzheimer's brain : the pathology and pathophysiolgical bases of Alzheimer's disease : implications for advancing diagnostic imaging -- section 2. Structural imaging to diagnose and measure Alzheimer-related brain changes -- section 3. Imaging of cerebral blood, flow, glucose metabolism, amyloid plaques and neurofibrilary tangles in AD -- section 4. Current advances in functional magnetic resonance imaging for detecting Alzheimer's disease -- section 5. Electromagnetic brain mapping : EEG, EP, ERP, and their magnetic equivalents -- section 6. Diffusion tensor imaging -- section 7. Magenetic resonance spectroscopy -- section 8. Longitudinal neuroimaging measures : windows into progression of disease and potential endpoints for clinical trials -- section 9. Vascular changes in the brain causing dementia and contributing to Alzheimer's disease -- section 10. Neuroimaging in the context of Alzheimer's disease. |
| Record Nr. | UNINA-9910781753103321 |
| Amsterdam, The Netherlands, : IOS Press, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of imaging the Alzheimer brain / / edited by J. Wesson Ashford ... [et al.]
| Handbook of imaging the Alzheimer brain / / edited by J. Wesson Ashford ... [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Amsterdam, The Netherlands, : IOS Press, 2011 |
| Descrizione fisica | 1 online resource (824 p.) |
| Disciplina |
618.97
618.976831 |
| Altri autori (Persone) | AshfordJ. Wesson |
| Collana | Advances in Alzheimer's disease |
| Soggetto topico |
Alzheimer's disease - Imaging
Brain - Imaging |
| ISBN |
6613289930
1-283-28993-8 9786613289933 1-60750-793-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. Imaging the Alzheimer's brain : the pathology and pathophysiolgical bases of Alzheimer's disease : implications for advancing diagnostic imaging -- section 2. Structural imaging to diagnose and measure Alzheimer-related brain changes -- section 3. Imaging of cerebral blood, flow, glucose metabolism, amyloid plaques and neurofibrilary tangles in AD -- section 4. Current advances in functional magnetic resonance imaging for detecting Alzheimer's disease -- section 5. Electromagnetic brain mapping : EEG, EP, ERP, and their magnetic equivalents -- section 6. Diffusion tensor imaging -- section 7. Magenetic resonance spectroscopy -- section 8. Longitudinal neuroimaging measures : windows into progression of disease and potential endpoints for clinical trials -- section 9. Vascular changes in the brain causing dementia and contributing to Alzheimer's disease -- section 10. Neuroimaging in the context of Alzheimer's disease. |
| Record Nr. | UNINA-9910974121103321 |
| Amsterdam, The Netherlands, : IOS Press, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Language, Dementia and Meaning Making : Navigating Challenges of Cognition and Face in Everyday Life / / by Heidi E. Hamilton
| Language, Dementia and Meaning Making : Navigating Challenges of Cognition and Face in Everyday Life / / by Heidi E. Hamilton |
| Autore | Hamilton Heidi E |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Palgrave Macmillan, , 2019 |
| Descrizione fisica | 1 online resource (254 pages) |
| Disciplina |
616.83
618.976831 |
| Soggetto topico |
Applied linguistics
Sociolinguistics Linguistics - Methodology Medical anthropology Social medicine Clinical health psychology Applied Linguistics Research Methods in Language and Linguistics Medical Anthropology Medical Sociology Health Psychology |
| ISBN |
9783030120214
303012021X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1: Knowing, remembering and performing in everyday life with dementia -- Chapter 2: Struggling to find the right words -- Chapter 3: Forgetting facts about oneself -- Chapter 4: Recalling what just happened -- Chapter 5: Recounting personal experiences from long ago -- Chapter 6: Engaging with physical objects in the here-and-now -- Chapter 7: Performing memory -- Chapter 8: Connections. |
| Record Nr. | UNINA-9910337722903321 |
|
Hamilton Heidi E
|
||
| Cham : , : Springer International Publishing : , : Imprint : Palgrave Macmillan, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||